BRISTOL MYERS SQUIBB

FDA approved Bristol Myers Squibb’s Opdivo Qvantig for subcutaneous use in treating various solid tumours, based on Phase III CheckMate-67T trial results. It offers faster administration and flexibility, maintaining efficacy and safety comparable to IV Opdivo.

Halozyme Therapeutics announced Takeda's HYQVIA® received Japanese regulatory approval for treating agammaglobulinemia or hypogammaglobulinemia, offering reduced dosing frequency with Halozyme's ENHANZE® technology.

Halozyme Therapeutics announced Japan's MHLW approved argenx's VYVDURA, co-formulated with Halozyme's ENHANZE® technology, for CIDP treatment. VYVDURA, a once-weekly subcutaneous injection, is the first FcRn blocker for CIDP, following its approval for gMG in Japan. The approval is based on the ADHERE Study, showing significant clinical improvement in patients.

FDA approved Bristol Myers Squibb's Opdivo Qvantig, co-formulated with Halozyme's ENHANZE, for subcutaneous use in adult solid tumor indications, based on Phase 3 CheckMate-67T study results showing comparable safety to IV Opdivo.

Halozyme announced argenx's VYVDURA, co-formulated with ENHANZE®, received Japan's MHLW approval for CIDP treatment, marking the first FcRn blocker for CIDP. Approved for weekly self-administered subcutaneous injection, it follows ADHERE Study's positive outcomes, offering a new treatment option in Japan.

Schizophrenia diagnoses are up to five times more common in Black Americans. The FDA approved Cobenfy, a new drug with fewer side effects, offering hope for better treatment adherence and quality of life.

FDA approved Bristol Myers Squibb's Opdivo in a subcutaneous injection, easing treatment for patients and potentially extending its patent life. This version, Opdivo Qvantig, is approved for various cancers, offering quicker administration and possibly reducing treatment costs. It uses Halozyme's hyaluronidase technology for improved drug delivery.

Opdivo Qvantig, the first subcutaneously administered PD-1 inhibitor, received FDA approval for treating solid tumors. It offers faster administration and comparable safety and efficacy to IV Opdivo, as shown in the Phase 3 CheckMate-67T trial.

FDA approved Opdivo Qvantig for subcutaneous use in treating solid tumors, offering faster administration and similar efficacy to IV Opdivo, based on the CheckMate-67T trial results.